SEC EDGAR · Company announcement
ICLR: 6-K company filing
Filed 6-K for an event or period dated 2026-09-30. Read the company report for its disclosures.
Follow ICLR- Became public
- Oct 27, 2026, 5:05 PM EDT
- Event / period date
- Sep 30, 2026
- Collected
- Nov 7, 2026, 8:26 PM EST
Why this is connected
This filing identifies ICON PLC as the issuer of the security. The company's SEC identifier connects it to ICLR.
Source evidence
Read the source excerpt or record
iclr-20260930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2026 Commission File Number: 333-08704 ICON plc (Translation of registrant's name into English) South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ ICON plc This report on Form 6-K is hereby incorporated by reference into the registration statements of ICON plc on Form S-8 (Registration Nos. 333-152802, 333-204153, 333-231527, 333-254891, 333-257578 and 333-282826) and on Form F-3 (Registration No. 333-278943), and this report on Form 6-K shall be deemed a part of each such registration statement from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished by ICON plc under the Securities Act of 1933 or the Securities Exchange Act of 1934. 1 GENERAL As used herein, “ICON plc”, “ICON”, "ICON Group", the “Company” and “we”, "our" or “us” refer to ICON public limited company and its consolidated subsidiaries, unless the context requires otherwise. Business ICON is a contract research organization (“CRO”), providing outsourced services on a global basis to pharmaceutical, biotechnology, medical device and government and public health organizations. We specialize in the strategic development, management and analysis of programs that support all stages of the clinical development process, from compound selection to Phase I-IV clinical studies. O ur vision is to be the healthcare intellig
Congressional trading in ICLR
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Sep 1, 2026$15K–$50K
Rep. Kevin Hern (R-OK-1)
Sold (partial) ICON Public Limited Company ICLR
$15K–$50K · Traded Aug 14, 2026 · disclosed Sep 1, 2026 · Joint
- Apr 3, 2026$100K–$250K
Rep. Kevin Hern (R-OK-1)
Sold ICON Public Limited Company ICLR
$100K–$250K · Traded Mar 5, 2026 · disclosed Apr 3, 2026 · Joint
- Mar 12, 2026$1K–$15K
Rep. Julia Letlow (R-LA-5)
Sold ICON Public Limited Company ICLR
$1K–$15K · Traded Feb 12, 2026 · disclosed Mar 12, 2026
- Sep 6, 2024$1K–$15K
Rep. John James (R-MI-10)
Sold ICON Public Limited Company ICLR
$1K–$15K · Traded Sep 4, 2024 · disclosed Sep 6, 2024
- Sep 2, 2024$1K–$15K
Rep. John James (R-MI-10)
Bought ICON Public Limited Company ICLR
$1K–$15K · Traded Jun 12, 2024 · disclosed Sep 2, 2024 · filed 82 days later
- Feb 14, 2023$1K–$15K
Rep. Kevin Hern (R-OK-1)
Sold ICON Public Limited Company ICLR
$1K–$15K · Traded Jan 31, 2023 · disclosed Feb 14, 2023 · Joint
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.